Cooler Heads, a medical device company, has raised $11 million in an oversubscribed Series A funding round to expand the manufacturing of Amma, the only FDA-cleared Portable Scalp Cooling System. Led by Mutual Capital Partners, the round also included participation from SHD Partners, Crescent Ridge VC, and others.
The Amma system helps chemotherapy patients preserve their hair and maintain privacy by cooling the scalp, which reduces blood flow to hair follicles and protects them from the effects of chemotherapy drugs. This continuous cooling system eliminates the need for dry ice or frequent cap changes, making it a more accessible alternative to traditional methods.
How the funding will be used: The funds will be used to increase manufacturing capacity, expand the commercial team, and develop the next generation of the product.
New board members: Along with Liz Todia Zambory (Mutual Capital), Mike Schotzinger of SHD Partners joined the company’s Board of Directors and Jason Pesterfield, the CEO of Elucent Medical, joined as an independent director.
KEY QUOTES:
“Hair loss is so emotionally devastating that 8% of patients eligible for chemotherapy refuse treatment. Amma is a user-friendly platform that helps infusion centers seamlessly add scalp cooling to their workflows. The American Medical Association’s decision to elevate scalp cooling reimbursement codes to Category I starting in January 2026 creates powerful momentum for us, reinforcing scalp cooling as an emerging standard of care.”
Kate Dilligan, breast cancer survivor, Founder, and CEO of Cooler Heads
“Our investment in Cooler Heads reflects our confidence in the ability of this leadership team to make scalp cooling available wherever patients are getting chemotherapy. Cooler Heads is not only improving care for patients, but for the first time making this therapy low friction for infusion centers.”
Liz Todia Zambory who led the Mutual Capital Partners team’s investment and will be joining the board
“In a process where so much is stripped away, scalp cooling helped me keep a part of myself intact, and that gave me strength.”
Jennifer George, who used Amma during 16 cycles of chemotherapy while being treated for early stage breast cancer in 2024
